Redwood Scientific (OTC:RSCI) Partners with Jeeva Clinical Trials to Initiate a Clinical Study on TBX-Free Oral Strips for Smoking and E-cigarette Cessation

The pharmaceutical sector is one of the more innovative industries out there, and investors are almost always on the lookout for standout companies. A company that has been doing path-breaking work in the sector is Redwood Scientific Technologies Inc. (OTC:RSCI), based out of New York, and on February 6, it made a significant new announcement. The company announced at the time that it had entered into an agreement with the firm Jeeva Clinical Trials.

As per the agreement, the two companies would collaborate on the launch of a clinical effectiveness study of Redwood Scientific Technologies’ TBX-Free oral strip products for cessation of smoking and e-cigarette use. Additionally, it was also noted that Redwood had also engaged the services of George Mason University, a top United States institution, to manage the efficacy study for its new product.

The Chief Executive Officer of the company, Jason Cardiff, spoke about the latest developments at the time. He noted that Redwood Scientific Technologies was committed to the development of effective and safe products that could help millions of people escape the clutches of nicotine addiction. Cardiff stated that the collaboration of the company with prestigious institutions would help make it possible. He went on to add that the company had recognized the brewing crisis, and hence, it was the aim of the management to bring the product to the market as soon as possible.

In this context, it should be noted that nicotine is one of the more addictive substances in the world and acts as both a sedative and a stimulant. As per reports, there are more than 8 million adults in the United States who use e-cigarettes and more than 28.3 million who smoke traditional cigarettes. More alarmingly, it had been revealed that more than 16.5% of high school students used tobacco.